Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer PRESS RELEASE Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren /...

Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections...

Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...

Memo Therapeutics increases Series C financing to CHF 45 million PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 million Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing...